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Evidence supports 
prediabetes treatment
In his News Feature on prediabetes 
(“Dubious diagnosis,” 8 March, p. 1026), 
C. Piller asserts that prediabetes diag-
noses and treatment may be ineffective
and sullied by conflicts of interest.
As current and former chairs of the
American Diabetes Association’s (ADA’s)
Professional Practice Committee [the
group that reviews and updates the
Standards of Medical Care in Diabetes
(Standards) each year], we disagree.
Prediabetes is a useful term to convey
future risk of diabetes, and recommenda-
tions for diabetes prevention are based on
best current evidence.
The ADA classifies prediabetes as a risk 
factor for diabetes that can be mitigated 
by lifestyle changes or, in limited circum-
stances, with the addition of metformin. 
Piller reports that prediabetes does little 
or no harm on its own and that fewer than 
2% of people with prediabetes progress to 
diabetes each year. The risk of progressing 
from prediabetes to diabetes varies accord-
ing to the diagnostic criteria used (1), but 
even a 2% progression rate per year would 
translate to nearly 1 of 5 people with predi-
abetes developing diabetes within 10 years. 
Also, many individuals with prediabetes 
have a multiplicity of risk, due to ethnicity, 
body weight, and other factors, and these 
may render their annual risk much higher.
In the online “Key takeaways” box 
(https://scim.ag/prediabetes), Piller states 
that “Many studies suggest that for most 
people the usual treatments for prediabetes, 
diet and exercise, do little to further reduce 
the risk of diabetes.” However, healthy eat-
ing and regular physical activity (2) have 
been shown (along with the medication 
metformin for select patients) to delay or 
prevent progression to diabetes (3–5). 
Accordingly, the Standards place a heavy 
emphasis on these lifestyle interventions.
Piller writes that the ADA lists costly 
medications for diabetes prevention, sold 
by pharmaceutical companies from which 
Professional Practice Committee members 
have collected “large sums.” We disagree 
that this funding affected the commit-
tee’s positions. No pharmaceutical agents 
have been FDA-approved for diabetes 
prevention, and the only recommended 
medication is metformin, which has been 
shown to be effective and safe (3, 6) and 
is available for as little as $4 per month 
[e.g., (7)], rendering the conflicts of inter-
est described in the article irrelevant to 
the current ADA recommendations for 
diabetes prevention. In fact, metformin 
may save costs over a 10-year period when 
used for diabetes prevention (6). The 
Standards of Care mentions pharmacologic 
agents other than metformin, including 
glucose-lowering and weight loss thera-
pies that have been studied for diabetes 
prevention (3), but these agents are not 
recommended by the ADA for diabetes pre-
vention. Additionally, the ADA states that 
metformin should be considered for those 
who have prediabetes, especially those who 
have a body mass index (BMI) of at least 
35 kg/m2, are under the age of 60 years, or 
have a history of gestational diabetes mel-
litus (2). These recommendations highlight 
the importance of risk stratification and 
individualization of therapy. 
We acknowledge that unanswered 
questions surrounding prediabetes and 
its management remain important issues 
that warrant open discussion. Indeed, the 
ADA has not shied away from such debate 
(8, 9). It is important to engage in these 
discussions with full consideration of the 
available evidence.
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